Efficacy News and Research

RSS

Kamada completes final analysis of phase III trial with intravenous Alpha-1 Antitrypsin (AAT), for hereditary AAT deficiency

Kamada has announced that it has completed the final analysis of its US Phase III trial with intravenous Alpha-1 Antitrypsin (AAT), for hereditary AAT deficiency.

26 Oct 2008

Nymox nears completion of benign prostatic hyperplasia drug trial

Nymox Pharmaceutical Corporation has announced that the Company's latest multi-center U.S. study of NX-1207, its investigational drug for the treatment of benign prostatic hyperplasia (BPH), is nearing completion.

23 Oct 2008

ZymoGenetics presents interim Interleukin 21 phase 2 results in renal cell cancer

ZymoGenetics, Inc. presented interim results today from a Phase 2 clinical trial evaluating Interleukin 21 (IL-21) in combination with Nexavar (sorafenib) tablets in patients with metastatic renal cell cancer.

22 Oct 2008

Peregrine Pharmaceuticals reports on phase II trial of Bavituximab plus Docetaxel in advanced breast cancer

Peregrine Pharmaceuticals, Inc. has announced that updated preliminary data from the first stage of its Phase II trial evaluating bavituximab in combination with docetaxel showed that 10 of 14 (71%) evaluable breast cancer patients achieved an objective tumor response according to RECIST criteria.

22 Oct 2008

Genentech announces phase III study of Avastin plus chemotherapy in adjuvant colon cancer will continue

Genentech, Inc. today announced that it has been informed by the National Surgical Adjuvant Breast and Bowel Project (NSABP) that an ongoing Phase III study (NSABP C-08) of Avastin (bevacizumab) plus chemotherapy in patients with early-stage colon cancer will continue as planned.

20 Oct 2008

Polio could be wiped out in Nigeria thanks to improved vaccine

A recently introduced polio vaccine is four times more effective at protecting children than previous vaccines and has the potential to eradicate type 1 polio in Nigeria if it reaches enough children, according to a study published today in the New England Journal of Medicine.

19 Oct 2008

Brain-derived neurotrophic factor may predict schizophrenia relapse

A factor that helps optimize brain formation and function may also provide clues about whether patients suffering with schizophrenia are headed toward relapse, researchers say.

16 Oct 2008

Biothera initiates second phase of metastatic colorectal cancer trial

Biothera has announced today it began dosing patients in the second arm of its metastatic colorectal cancer (mCRC) trial in August.

16 Oct 2008

neuMirRx issued U.S. patent for "methods for enhancing solubility of compounds

neuMirRx Corp today welcomed the issuance of U.S. patent 7,345,093, entitled "Methods for Enhancing Solubility of Compounds" which covers novel formulation methods to enhance the solubility of hydrophobic compounds.

15 Oct 2008

People with severe obstructive sleep apnea often have poor diets

A study in the October 15 issue of the Journal of Clinical Sleep Medicine shows that unrelated to obesity, people with severe SDBs consume a more unhealthy diet, which may be a factor contributing to greater cardiovascular morbidity and mortality. These findings were most evident among women.

15 Oct 2008

Addex Parkinson's product progressing in early clinical trials

Addex Pharmaceuticals has announced that it has completed the first part of a two-part Phase I clinical trial to evaluate the newly developed modified release formulation of ADX48621. ADX48621 is scheduled to start a Phase IIa proof of concept study for the treatment of levodopa associated dyskinesia in Parkinson's disease during the first half of 2009.

15 Oct 2008

Tribendimidine shows promise for intestinal worm infections

Researchers have reported positive results from a safety and efficacy study pertaining to tribendimidine, a broad-based treatment for intestinal worm infections.

14 Oct 2008

Antiretroviral drug efavirenz associated with better outcomes in HIV-infected adults

A study led by researchers at the Johns Hopkins Bloomberg School of Public Health found that HIV-infected patients taking the antiretroviral drug efavirenz were more likely to adhere to treatment and less likely to experience virologic failure and death compared to patients taking nevirapine.

14 Oct 2008

Marked increase in the use of herbal medicines by Australians

Australian researchers have found that the most popular herbal medicines used by Australians are aloe vera, garlic and green tea.

13 Oct 2008

Quark Pharmaceuticals' siRNAs examined alone and in xombination with chemotherapy

Quark Pharmaceuticals, Inc. has announced that the journal Cancer Research published results on efficacy of siRNA targeting its proprietary target gene against non-small cell lung cancer (NSCLC) in the edition dated October 1, 2008.

12 Oct 2008

Kamada reports positive data with inhaled Alpha-1 Antitrypsin in cystic fibrosis

Kamada has announced today positive data from its Phase II study evaluating inhaled Alpha-1 Antitrypsin (AAT) delivered via an Investigational eFlow Nebulizer System (PARI Pharma GmbH), in the treatment of cystic fibrosis. The results demonstrate the product has an excellent safety profile and shows promising signs of efficacy, as indicated by a reduction in lung inflammation.

12 Oct 2008

FDA continues review of Takeda's NDA for Alogliptin

Takeda Pharmaceutical Company Limited has announced that Takeda Global Research and Development Center, Inc., a wholly owned United States (U.S.) subsidiary, received notification that the U.S. Food and Drug Administration (FDA) will not be able to complete its review of the alogliptin New Drug Application (NDA) by the Prescription Drug User Fee Act (PDUFA) date of October 27, 2008.

12 Oct 2008

FDA approves Rapaflo for treatment of symptoms due to benign prostatic hyperplasia

The U.S. Food and Drug Administration today approved Rapaflo (silodosin) capsules for the treatment of symptoms due to benign prostatic hyperplasia (BPH), a condition also known as an enlarged prostate.

12 Oct 2008

Little use of biological alternatives to chemical pesticides

The increasing demands from many consumers in this day and age for fruit and vegetables which have been grown free of chemical pesticides, has put scientists under pressure to find biological alternatives.

12 Oct 2008

Battling cancer at the single cell level

New research suggests that the identification and examination of key cell signaling events required for initiation and progression of cancer might be best accomplished at the single cell level. The research, published by Cell Press in the October issue of the journal Cancer Cell, provides new insight that may lead to better diagnosis and treatment of some complex cancers.

6 Oct 2008

Efficacy News and Research

Kamada completes final analysis of phase III trial with intravenous Alpha-1 Antitrypsin (AAT), for hereditary AAT deficiency

Nymox nears completion of benign prostatic hyperplasia drug trial

ZymoGenetics presents interim Interleukin 21 phase 2 results in renal cell cancer

Peregrine Pharmaceuticals reports on phase II trial of Bavituximab plus Docetaxel in advanced breast cancer

Genentech announces phase III study of Avastin plus chemotherapy in adjuvant colon cancer will continue

Polio could be wiped out in Nigeria thanks to improved vaccine

Brain-derived neurotrophic factor may predict schizophrenia relapse

Biothera initiates second phase of metastatic colorectal cancer trial

neuMirRx issued U.S. patent for "methods for enhancing solubility of compounds

People with severe obstructive sleep apnea often have poor diets

Addex Parkinson's product progressing in early clinical trials

Tribendimidine shows promise for intestinal worm infections

Antiretroviral drug efavirenz associated with better outcomes in HIV-infected adults

Marked increase in the use of herbal medicines by Australians

Quark Pharmaceuticals' siRNAs examined alone and in xombination with chemotherapy

Kamada reports positive data with inhaled Alpha-1 Antitrypsin in cystic fibrosis

FDA continues review of Takeda's NDA for Alogliptin

FDA approves Rapaflo for treatment of symptoms due to benign prostatic hyperplasia

Little use of biological alternatives to chemical pesticides

Battling cancer at the single cell level

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News